



IRW

Docket No. 60807-AA-PCT-US/JPW/GJG/DJK

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Alexander Gad and Dora Lis  
U.S. Serial No.: 10/792,311 Examiner: P. Huynh  
Filed : March 2, 2004 Group Art Unit: 1644  
For : COPOLYMER 1 RELATED POLYPEPTIDES FOR  
USE AS MOLECULAR WEIGHT MARKERS AND FOR  
THERAPEUTIC USE

1185 Avenue of the Americas  
New York, New York 10036  
April 20, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT PURSUANT TO 37 C.F.R. §1.97(c)(2)**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following publications which are listed again on the attached Form PTO-1449 (**Exhibit A**). Copies of Reference Items 1-2, (**Exhibits 1-2**) are also enclosed.

1. Sela, M., et al., "Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases" Vaccine, 1992, Vol. 10, Issue 14, 991-999 (**Exhibit 1**); and
2. Supplemental European Search Report issued March 14, 2005 in connection with European Patent Application No. EP 99949923.9 (**Exhibit 2**).

Applicants : Alexander Gad and Dora Lis  
Serial No. : 10/792,311  
Filed : March 2, 2004  
Page 2

This Supplemental Information Disclosure Statement is being submitted after the issuance of a first Office Action on the merits in connection with the subject application but before the mailing date of any final action. Pursuant to 37 C.F.R. §1.97(c), an information disclosure statement shall be considered by the U.S. Patent Office after the mailing date of a first Office Action if it is accompanied by a statement under 37 C.F.R. §1.97(e) or the fee set forth in §1.17(p).

Reference item 1 was cited in a March 14, 2005 Supplemental European Search Report issued in connection with European Application No. EP 99949923.9, the counterpart European application to the subject application. Applicants have submitted the fee set forth in 37 C.F.R. §1.17(p) with their March 24, 2005 Supplemental Information Disclosure Statement.


Applicants request that the Examiner review the publications and make them of record in the subject application.

Applicants : Alexander Gad and Dora Lis  
Serial No. : 10/792,311  
Filed : March 2, 2004  
Page 3

No fee is deemed necessary in connection with the filing of this Third Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.




Respectfully submitted,



John P. White  
Registration No. 28,678  
Gary J. Gershik  
Registration No. 39,992  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
John P. White Date  
Reg. No. 28,678  
Gary J. Gershik  
Reg. No. 39,992



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60807-AA-PCT-  
US/JPW/GJG/DJKU.S. Serial No.  
10/792,311INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants:  
Alexander Gad and Dora LisFiling Date:  
March 2, 2004Group Art Unit  
1644

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Sela, M., et al., "Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases" Vaccine, 1992, Vol. 10, Issue 14, 991-999
	Supplemental European Search Report issued March 14, 2005 in connection with European Patent Application No. EP 99949923.9

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.